東華大學圖書館 |

語系: 繁體中文

說明(常見問題)

回圖書館首頁

手機版館藏查詢

登入

回首頁

切換: 標籤 | MARC模式 | ISBD

Dissecting roles of estrogen recepto...

University of Colorado Health Sciences Center.

FindBook

Google Book

Amazon

博客來

Dissecting roles of estrogen receptors in breast cancer lymphatic metastasis.

紀錄類型:	書目-語言資料,印刷品 : Monograph/item
正題名/作者:	Dissecting roles of estrogen receptors in breast cancer lymphatic metastasis./
作者:	Harrell, Joshua C.
面頁冊數:	175 p.
附註:	Adviser: Kathryn B. Horwitz.
Contained By:	Dissertation Abstracts International68-05B.
標題:	Biology, Molecular. -
電子資源:	http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3264539
ISBN:	9780549033110

Dissecting roles of estrogen receptors in breast cancer lymphatic metastasis.
Harrell, Joshua C.

Dissecting roles of estrogen receptors in breast cancer lymphatic metastasis. - 175 p.

Adviser: Kathryn B. Horwitz.

Thesis (Ph.D.)--University of Colorado Health Sciences Center, 2007.

The lymphatic system is a common avenue for the spread of breast cancer cells. If primary tumors are estrogen (ER) and/or progesterone (PR) receptor positive, then the likelihood that lymph node (LN) metastases express receptors exceeds 80%. However, little is known about the role of hormones in breast cancer spread or the effects of the LN microenvironment on hormone responsiveness. We developed ER+ metastasis models using ZsGreen labeled ER+ human breast cancer cells. Tumors and metastases were tracked in living mice by fluorescent whole-body and intravital imaging. Tumor growth was estrogen dependent and required for intratumoral lymphangiogenesis. Seventy-five percent of estrogen treated tumors generate LN metastases. "Triads" of primary tumors, tumor-filled draining lymphatic vessels, and tumor-filled LNs from the same mouse showed that: (a) proliferation was higher in the LN than in the primary tumor. (b) High ER levels were extensively downregulated by estradiol in primary tumors. However, there was partial failure of ER downregulation in LNs associated with (c) reduced PR expression. (d) The hyaluronan receptor, CD44 was sparsely expressed in primary tumor cells but homogeneously overexpressed in cells transiting the lymphatics and populating LNs, suggesting that CD44 targets tumor cells for transport to LNs. To follow up on the observations that ER have reduced function in the LN microenvironment we developed a fluorescent xenograft model in which estradiol was withdrawn after the development of ER+ LN metastasis. Estradiol-withdrawal combined with laser-capture microdissection, gene expression profiling, and immunohistochemistry was used to assess estrogen responsiveness of primary tumor xenografts and matched LN metastases. Genes regulated by the tumor cell microenvironment, by hormones, or both were identified. Gene expression data confirmed the estrogen insensitivity of ER+ LN metastases. Fewer genes were estradiol regulated in breast cancer cells at the metastatic site. Interestingly, seventy-five of the genes were estradiol regulated in the opposite direction in tumors and LN metastases. We speculate that current estrogen withdrawal or antiestrogen therapies may differentially affect breast cancer cells growing within the breast and in the LNs, and that the LN microenvironment renders cancer cells relatively resistant to estrogen suppression therapies.

ISBN: 9780549033110Subjects--Topical Terms:

1017719
Biology, Molecular.

Dissecting roles of estrogen receptors in breast cancer lymphatic metastasis.
LDR:03320nam 2200277 a 45 001 962593
005 20110830
008 110831s2007 ||||||||||||||||| ||eng d
020 $a 9780549033110
035 $a (UMI)AAI3264539
035 $a AAI3264539
040 $a UMI $c UMI
100 1 $a Harrell, Joshua C. $3 1285653
245 1 0 $a Dissecting roles of estrogen receptors in breast cancer lymphatic metastasis.
300 $a 175 p.
500 $a Adviser: Kathryn B. Horwitz.
500 $a Source: Dissertation Abstracts International, Volume: 68-05, Section: B, page: 2819.
502 $a Thesis (Ph.D.)--University of Colorado Health Sciences Center, 2007.
520 $a The lymphatic system is a common avenue for the spread of breast cancer cells. If primary tumors are estrogen (ER) and/or progesterone (PR) receptor positive, then the likelihood that lymph node (LN) metastases express receptors exceeds 80%. However, little is known about the role of hormones in breast cancer spread or the effects of the LN microenvironment on hormone responsiveness. We developed ER+ metastasis models using ZsGreen labeled ER+ human breast cancer cells. Tumors and metastases were tracked in living mice by fluorescent whole-body and intravital imaging. Tumor growth was estrogen dependent and required for intratumoral lymphangiogenesis. Seventy-five percent of estrogen treated tumors generate LN metastases. "Triads" of primary tumors, tumor-filled draining lymphatic vessels, and tumor-filled LNs from the same mouse showed that: (a) proliferation was higher in the LN than in the primary tumor. (b) High ER levels were extensively downregulated by estradiol in primary tumors. However, there was partial failure of ER downregulation in LNs associated with (c) reduced PR expression. (d) The hyaluronan receptor, CD44 was sparsely expressed in primary tumor cells but homogeneously overexpressed in cells transiting the lymphatics and populating LNs, suggesting that CD44 targets tumor cells for transport to LNs. To follow up on the observations that ER have reduced function in the LN microenvironment we developed a fluorescent xenograft model in which estradiol was withdrawn after the development of ER+ LN metastasis. Estradiol-withdrawal combined with laser-capture microdissection, gene expression profiling, and immunohistochemistry was used to assess estrogen responsiveness of primary tumor xenografts and matched LN metastases. Genes regulated by the tumor cell microenvironment, by hormones, or both were identified. Gene expression data confirmed the estrogen insensitivity of ER+ LN metastases. Fewer genes were estradiol regulated in breast cancer cells at the metastatic site. Interestingly, seventy-five of the genes were estradiol regulated in the opposite direction in tumors and LN metastases. We speculate that current estrogen withdrawal or antiestrogen therapies may differentially affect breast cancer cells growing within the breast and in the LNs, and that the LN microenvironment renders cancer cells relatively resistant to estrogen suppression therapies.
590 $a School code: 0831.
650 4 $a Biology, Molecular. $3 1017719
650 4 $a Health Sciences, Oncology. $3 1018566
690 $a 0307
690 $a 0992
710 2 $a University of Colorado Health Sciences Center. $3 1023815
773 0 $t Dissertation Abstracts International $g 68-05B.
790 $a 0831
790 1 0 $a Horwitz, Kathryn B., $e advisor
791 $a Ph.D.
792 $a 2007
856 4 0 $u http://pqdd.sinica.edu.tw/twdaoapp/servlet/advanced?query=3264539